Results 31 to 40 of about 7,353 (153)

Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease

Reumatismo, 2019
Behçet’s disease is a chronic autoinflammatory disorder that usually presents with recurrent oral and genital ulcers, uveitis, skin lesions and arthritis.
L.B. Santos, J. Rigueira, A.P. Vilas
doaj   +1 more source

Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aims to evaluate the tolerability and effectiveness of the off‐label use of rimegepant as acute migraine treatment in adolescents. Background Calcitonin gene‐related peptide (CGRP) levels are elevated during migraine attacks.
Konstantinos Tourlas, Sruthi Ilangovan, Chelsea White, Samantha L. Irwin, Sara Pavitt   +4 more
wiley   +1 more source

Hughes-Stovin syndrome: A rare cause of hemoptysis

Lung India, 2011
Multiple pulmonary artery aneurysms are seen along with venous thrombosis in Hughes-Stovin syndrome, which many investigators believe is an incomplete form of Behcet′s disease.
Naseer A Choh, Majid Jehangir, Khalid Mohiuddin Mir, Sanaullah Kuchay, Nisar A Wani   +4 more
doaj   +1 more source

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, Falk G. Bechara, Farida Benhadou, Joana Cabete, Raffaele Dante Caposiena Caro, Giovanni Damiani, Maia Delage Toriel, Veronique Del Marmol, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Evgeniya Hristakieva, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Niamh Kearney, Brian Kirby, Natalia Kirsten, Piotr K. Krajewski, Vesta Kucinskiene, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Francesca Prignano, Tadas Raudonis, Hans Christian Ring, Marco Romanelli, Samed Şahin, Ditte M. L. Saunte, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. Van Der Zee, Kelsey Van Straalen, Christos C. Zouboulis   +41 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet’s Disease

Gut and Liver, 2018
Background/Aims The cumulative surgery rate and postoperative relapse of intestinal Behcet’s disease (BD) have been reported to be high. This study aimed to establish a scoring system based on follow-up endoscopic findings that can predict intestinal BD ...
Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon   +5 more
doaj   +1 more source

Dermatologic Findings of RELA‐Associated Autoinflammatory Disease

Pediatric Dermatology, EarlyView.
ABSTRACT Variants in the gene RELA have been implicated in a monogenic, hereditary form of Behcet's‐like syndrome. This case series describes the dermatologic manifestations of three patients with identified RELA‐associated autoinflammatory disease.
Elizabeth Nourse, Vidya Sivaraman, Catherine G. Chung, Shoghik Akoghlanian, Esteban Fernandez Faith   +4 more
wiley   +1 more source

Relationship between dietary histamine intake and clinical parameters in Behçet syndrome

Gülhane Tıp Dergisi
Aims: This study investigated histamine intake and its associations with clinical and biochemical findings in patients with Behçet syndrome. Methods: Patients with Behçet syndrome were prospectively enrolled using a cross-sectional, multicenter, and ...
Hüsna Ercin, Nesli Ersoy
doaj   +1 more source

Transition From Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Juvenile dermatomyositis (JDM) is a rare childhood inflammatory myopathy, whereas spondyloarthritis (SpA) is an inflammatory arthropathy characterized by enthesitis and peripheral or axial involvement. We describe a series of patients diagnosed with JDM in childhood who later fulfilled classification criteria for SpA, a sequential phenotype ...
Austen Grooms, Ioannis Karageorgiou, Kerry Mychaliska, James Birmingham   +3 more
wiley   +1 more source

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vasculitis flares and irAEs in this population.
Juan Sevillano, Noha Abdel‐Wahab, Yixuan Zhou, Juan I. Ruiz, Maria E. Suarez‐Almazor   +4 more
wiley   +1 more source